NOVAVAX Revenue and Competitors

Gaithersburg, Sweden

Location

$2.4B

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • NOVAVAX's estimated annual revenue is currently $1.2B per year.(i)
  • NOVAVAX's estimated revenue per employee is $902,256
  • NOVAVAX's total funding is $2.4B.
  • NOVAVAX's current valuation is $8.4B. (January 2022)

Employee Data

  • NOVAVAX has 1330 Employees.(i)
  • NOVAVAX grew their employee count by -6% last year.

NOVAVAX's People

NameTitleEmail/Phone
1
Senior Director Strategic Alliance Business OperationsReveal Email/Phone
2
EVP and General Manager, InfluenzaReveal Email/Phone
3
VP Clinical ResearchReveal Email/Phone
4
Senior ServiceNow AdministratorReveal Email/Phone
5
Director QA/QC Technical OperationsReveal Email/Phone
6
Senior Manager-Process Science and Validation, Drug ProductReveal Email/Phone
7
Chief Operations OfficerReveal Email/Phone
8
UKG - HRISReveal Email/Phone
9
Formulation Development Process Technology, Protein Vaccine Team MemberReveal Email/Phone
10
Senior Director, Public Policy & Market AccessReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$69340M1073104%N/A$308.4B
#2
$141.7M3516%N/AN/A
Add Company

What Is NOVAVAX?

Novavax AB is a fully owned subsidiary of Novavax Inc. a late-stage biotechnology company focused on the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. Our recombinant nanoparticles and Matrix-Mᅢᄁ¬ダᅡᄁ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Product Pipeline Our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("RSV"), seasonal influenza, pandemic influenza, and Ebola virus ("EBOV"). We have additional preclinical-stage programs for a variety of infectious diseases. Corporate Overview Novavax is headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.

keywords:N/A

$2.4B

Total Funding

1330

Number of Employees

$1.2B

Revenue (est)

-6%

Employee Growth %

$8.4B

Valuation

N/A

Accelerator

NOVAVAX News

2022-04-20 - Novavax nears FDA advisory meeting date

Novavax signaled a positive outlook for its vaccine pipeline Wednesday with announcements at the World Vaccine Congress and an update on its...

2022-04-19 - Japan approves Novavax as fourth COVID-19 vaccine amid new surge

Japan's health ministry on Tuesday formally approved Novavax's COVID-19 vaccine, a fourth foreign-developed tool to combat the infections as...

2022-04-17 - Japan health ministry panel approves Novavax's COVID-19 vaccine

A Japanese Health Ministry committee said on Monday it has approved Novavax Inc's COVID-19 vaccine, setting the stage for full approval of...

2021-11-15 - Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373

SK bioscience submits application for NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for BLA, to South Korea's MFDS GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation ...

2021-11-04 - Novavax Reports Third Quarter 2021 Financial Results and Operational Highlights

GAITHERSBURG, Md., Nov. 4, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the third quarter ended ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1650M2355-18%$36.5M
#2
$1113.6M38675%N/A
#3
$706.1M4945N/AN/A
#4
$718.4M50316%N/A
#5
$2188M61537%N/A